Overview

* OptimizeRx ( OPRX ) Q2 revenue grows 55% yr/yr, beating analyst expectations, per LSEG data

* Adjusted EBITDA for Q2 beats consensus, reflecting strong operational performance

* Co raises full-year 2025 guidance for revenue and adjusted EBITDA

Outlook

* Company raises 2025 revenue guidance to $104 mln-$108 mln

* OptimizeRx ( OPRX ) expects 2025 adjusted EBITDA of $14.5 mln-$17.5 mln

Result Drivers

* AI TECHNOLOGY - OptimizeRx ( OPRX ) attributes revenue growth to market-leading patient finding AI technology

* DEBT REDUCTION - Co paid down $4.5 mln on term loan, exceeding scheduled payments

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 Beat $29.20 $22.30

Revenue mln mln (7

Analysts

)

Q2 Beat $4.50 $206,200

Adjusted mln (6

Net Analysts

Income )

Q2 Beat $5.80 $1.31

Adjusted mln mln (7

EBITDA Analysts

)

Q2 Cash $16.60

& mln

Investme

nts

Q2 Gross $18.60

Profit mln

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the online services peer group is "buy"

* Wall Street's median 12-month price target for OptimizeRx Corp ( OPRX ) is $16.00, about 22% above its August 6 closing price of $12.48

* The stock recently traded at 21 times the next 12-month earnings vs. a P/E of 20 three months ago

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)